標的免疫療法薬のトリプレット併用による標準治療の比較
プラチナ耐性再発上皮の女性におけるオラパリブとセディラニブまたはデュルバルマブ(MEDI4736)およびセディラニブまたは標準治療化学療法と比較したトリプレット療法(オラパリブおよびセディラニブと組み合わせた PD-L1 阻害剤デュルバルマブ(MEDI4736))の無作為化第 II 相試験以前にベバシズマブを投与された卵巣がん、原発性腹膜がんまたは卵管がん
This phase II trial studies the possible benefits of treatment with different combinations of the drugs durvalumab, olaparib and cediranib vs. the usual treatment in patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back after a period of improvement with platinum therapy (recurrent platinum resistant). Usual treatment is the type of treatment most patients with this condition receive if they are not part of a clinical study. Combination therapies studied in this trial include MEDI4736 (durvalumab) plus olaparib and cediranib, durvalumab and cediranib, or olaparib and cediranib. Monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumors cells to grow and spread. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Cediranib may stop the growth of tumor cells by blocking VEGF (an enzyme). needed for cell growth. Giving different combinations of durvalumab, olaparib and cediranib may work better in increasing the duration of time that the cancer does not progress compared to the usual treatment.
調査の概要
状態
条件
- 卵巣血清粘液性癌
- 再発性卵巣高悪性度漿液性腺癌
- プラチナ製剤抵抗性卵巣癌の再発
- 卵管粘液腺癌
- 再発卵管明細胞腺癌
- 再発卵管子宮内膜腺癌
- 再発卵管未分化癌
- 再発性卵巣明細胞腺癌
- 再発性卵巣子宮内膜腺癌
- 再発卵巣未分化がん
- 再発プラチナ抵抗性卵管がん
- 再発プラチナ抵抗性原発性腹膜癌
- 再発原発性腹膜明細胞腺癌
- 再発原発性腹膜子宮内膜腺癌
- 再発原発性腹膜未分化癌
- プラチナ難治性卵管がん
- プラチナ難治性卵巣癌
- プラチナ難治性原発性腹膜癌
- 再発卵管高悪性度漿液性腺癌
- 再発卵管粘液腺癌
- 再発卵管移行上皮がん
- 再発性低悪性度卵管漿液性腺癌
- 再発性卵巣低悪性度漿液性腺癌
- 再発性卵巣粘液腺癌
- 再発性卵巣血清粘液性癌
- 再発性卵巣移行上皮がん
- 再発原発性腹膜高悪性度漿液性腺癌
- 再発原発性腹膜低悪性度漿液性腺癌
- 再発原発性腹膜移行上皮がん
- 難治性卵管明細胞腺癌
- 難治性卵管子宮内膜腺癌
- 難治性卵管高悪性度漿液性腺癌
- 難治性卵管粘液腺癌
- 難治性卵管移行上皮がん
- 難治性卵管未分化癌
- 難治性低悪性度卵管漿液性腺癌
- 難治性卵巣明細胞腺癌
- 難治性卵巣子宮内膜腺癌
- 難治性卵巣高悪性度漿液性腺癌
- 難治性卵巣低悪性度漿液性腺癌
- 難治性卵巣粘液腺癌
- 難治性卵巣血清粘液性癌
- 難治性卵巣移行上皮がん
- 難治性卵巣未分化癌
- 難治性原発性腹膜明細胞腺癌
- 難治性原発性腹膜子宮内膜腺癌
- 難治性原発性腹膜高悪性度漿液性腺癌
- 難治性原発性腹膜低悪性度漿液性腺癌
- 難治性の原発性腹膜移行上皮がん
- 難治性原発性腹膜未分化癌
介入・治療
- 薬:Paclitaxel
- 手順:Computed Tomography
- 手順:Magnetic Resonance Imaging
- 手順:Echocardiography Test
- 手順:Multigated Acquisition Scan
- 手順:Biospecimen Collection
- 薬:Cediranib Maleate
- 薬:Olaparib
- 薬:Pegylated Liposomal Doxorubicin Hydrochloride
- 薬:Topotecan Hydrochloride
- 手順:Computed Tomography with Contrast
- 生物学的:Durvalumab
詳細な説明
PRIMARY OBJECTIVE:
I. To assess the efficacy of the combinations durvalumab (MEDI4736) plus olaparib and cediranib, durvalumab (MEDI4736) plus cediranib, or olaparib and cediranib, as measured by progression-free survival (PFS), as compared to physician's choice standard of care chemotherapy, in patients with recurrent platinum-resistant ovarian, primary peritoneal or fallopian tube cancer who had prior bevacizumab.
SECONDARY OBJECTIVES:
I. To assess the efficacy of the combinations durvalumab (MEDI4736) plus olaparib and cediranib, durvalumab (MEDI4736) plus cediranib, or olaparib and cediranib, as measured by overall response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as compared to physician's choice standard of care chemotherapy, in patients with recurrent platinum-resistant ovarian, primary peritoneal or fallopian tube cancer who had prior bevacizumab.
II. To assess the efficacy of the combinations durvalumab (MEDI4736) plus olaparib and cediranib, durvalumab (MEDI4736) plus cediranib, or olaparib and cediranib, as measured by overall survival (OS), as compared to physician's choice standard of care chemotherapy, in patients with recurrent platinum-resistant ovarian, primary peritoneal or fallopian tube cancer who had prior bevacizumab.
OUTLINE: Patients are randomized to 1 of 4 arms.
ARM I: Patients receive paclitaxel intravenously (IV) over 60 minutes on days 1, 8, and 15, or pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1, or topotecan hydrochloride IV over 30 minutes on days 1, 8 and 15 or days 1-5 per the discretion of the treating physician. Cycles repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo echocardiography (ECHO) or multigated acquisition scan (MUGA) during screening and as clinically indicated on study. Patients also undergo collection of blood and computed tomography (CT) with contrast during screening, and CT or magnetic resonance imaging (MRI) scans throughout the trial.
ARM II: Patients receive durvalumab IV over 60 minutes on day 1, cediranib maleate orally (PO) once daily (QD) Monday through Friday, and olaparib PO twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.
ARM III: Patients receive durvalumab IV over 60 minutes on day 1 and cediranib maleate PO QD Monday through Friday. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.
ARM IV: Patients receive cediranib maleate PO QD on days 1-28 and olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.
After completion of study treatment, patients are followed up periodically for up to 5 years.
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Alaska
-
Anchorage、Alaska、アメリカ、98508
- Anchorage Associates in Radiation Medicine
-
Anchorage、Alaska、アメリカ、99508
- Alaska Breast Care and Surgery LLC
-
Anchorage、Alaska、アメリカ、99508
- Alaska Oncology and Hematology LLC
-
Anchorage、Alaska、アメリカ、99508
- Alaska Women's Cancer Care
-
Anchorage、Alaska、アメリカ、99508
- Anchorage Oncology Centre
-
Anchorage、Alaska、アメリカ、99508
- Katmai Oncology Group
-
Anchorage、Alaska、アメリカ、99508
- Providence Alaska Medical Center
-
Anchorage、Alaska、アメリカ、99504
- Anchorage Radiation Therapy Center
-
Fairbanks、Alaska、アメリカ、99701
- Fairbanks Memorial Hospital
-
-
Arizona
-
Goodyear、Arizona、アメリカ、85338
- CTCA at Western Regional Medical Center
-
Phoenix、Arizona、アメリカ、85004
- Cancer Center at Saint Joseph's
-
-
Arkansas
-
Fort Smith、Arkansas、アメリカ、72903
- Mercy Hospital Fort Smith
-
Hot Springs、Arkansas、アメリカ、71913
- CHI Saint Vincent Cancer Center Hot Springs
-
Little Rock、Arkansas、アメリカ、72205
- University of Arkansas for Medical Sciences
-
-
California
-
Arroyo Grande、California、アメリカ、93420
- Mission Hope Medical Oncology - Arroyo Grande
-
Auburn、California、アメリカ、95602
- Sutter Auburn Faith Hospital
-
Auburn、California、アメリカ、95603
- Sutter Cancer Centers Radiation Oncology Services-Auburn
-
Berkeley、California、アメリカ、94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Burbank、California、アメリカ、91505
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
-
Cameron Park、California、アメリカ、95682
- Sutter Cancer Centers Radiation Oncology Services-Cameron Park
-
Castro Valley、California、アメリカ、94546
- Eden Hospital Medical Center
-
Concord、California、アメリカ、94520
- John Muir Medical Center-Concord
-
Davis、California、アメリカ、95616
- Sutter Davis Hospital
-
Duarte、California、アメリカ、91010
- City of Hope Comprehensive Cancer Center
-
Fremont、California、アメリカ、94538
- Palo Alto Medical Foundation-Fremont
-
Lancaster、California、アメリカ、93534
- City of Hope Antelope Valley
-
Los Angeles、California、アメリカ、90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles、California、アメリカ、90033
- Los Angeles General Medical Center
-
Modesto、California、アメリカ、95355
- Memorial Medical Center
-
Mountain View、California、アメリカ、94040
- Palo Alto Medical Foundation-Camino Division
-
Mountain View、California、アメリカ、94040
- Palo Alto Medical Foundation-Gynecologic Oncology
-
Palo Alto、California、アメリカ、94301
- Palo Alto Medical Foundation Health Care
-
Roseville、California、アメリカ、95661
- Sutter Cancer Centers Radiation Oncology Services-Roseville
-
Roseville、California、アメリカ、95661
- Sutter Roseville Medical Center
-
Sacramento、California、アメリカ、95816
- Sutter Medical Center Sacramento
-
San Francisco、California、アメリカ、94115
- California Pacific Medical Center-Pacific Campus
-
San Luis Obispo、California、アメリカ、93401
- Pacific Central Coast Health Center-San Luis Obispo
-
Santa Cruz、California、アメリカ、95065
- Palo Alto Medical Foundation-Santa Cruz
-
Santa Maria、California、アメリカ、93444
- Mission Hope Medical Oncology - Santa Maria
-
Santa Rosa、California、アメリカ、95403
- Sutter Pacific Medical Foundation
-
South Pasadena、California、アメリカ、91030
- City of Hope South Pasadena
-
Sunnyvale、California、アメリカ、94086
- Palo Alto Medical Foundation-Sunnyvale
-
Upland、California、アメリカ、91786
- City of Hope Upland
-
Vallejo、California、アメリカ、94589
- Sutter Solano Medical Center/Cancer Center
-
Walnut Creek、California、アメリカ、94598
- John Muir Medical Center-Walnut Creek
-
-
Colorado
-
Aurora、Colorado、アメリカ、80012
- Rocky Mountain Cancer Centers-Aurora
-
Boulder、Colorado、アメリカ、80304
- Rocky Mountain Cancer Centers-Boulder
-
Centennial、Colorado、アメリカ、80112
- Rocky Mountain Cancer Centers - Centennial
-
Colorado Springs、Colorado、アメリカ、80907
- Penrose-Saint Francis Healthcare
-
Colorado Springs、Colorado、アメリカ、80907
- Rocky Mountain Cancer Centers-Penrose
-
Denver、Colorado、アメリカ、80210
- AdventHealth Porter
-
Durango、Colorado、アメリカ、81301
- Mercy Medical Center
-
Durango、Colorado、アメリカ、81301
- CommonSpirit Cancer Center Mercy
-
Lakewood、Colorado、アメリカ、80228
- CommonSpirit Saint Anthony Hospital Cancer Center
-
Littleton、Colorado、アメリカ、80120
- Rocky Mountain Cancer Centers-Littleton
-
Littleton、Colorado、アメリカ、80122
- AdventHealth Littleton
-
Lone Tree、Colorado、アメリカ、80124
- Rocky Mountain Cancer Centers-Sky Ridge
-
Longmont、Colorado、アメリカ、80501
- Longmont United Hospital
-
Longmont、Colorado、アメリカ、80501
- Rocky Mountain Cancer Centers-Longmont
-
Loveland、Colorado、アメリカ、80539
- Banner North Colorado Medical Center - Loveland Campus
-
Parker、Colorado、アメリカ、80138
- AdventHealth Parker
-
Pueblo、Colorado、アメリカ、81004
- Saint Mary Corwin Medical Center
-
-
Connecticut
-
Danbury、Connecticut、アメリカ、06810
- Danbury Hospital
-
Norwalk、Connecticut、アメリカ、06856
- Norwalk Hospital
-
-
Florida
-
Pensacola、Florida、アメリカ、32504
- Sacred Heart Hospital
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30342
- Northside Hospital
-
Newnan、Georgia、アメリカ、30265
- CTCA at Southeastern Regional Medical Center
-
-
Hawaii
-
Honolulu、Hawaii、アメリカ、96813
- Queen's Medical Center
-
Honolulu、Hawaii、アメリカ、96826
- Kapiolani Medical Center for Women and Children
-
-
Idaho
-
Boise、Idaho、アメリカ、83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise、Idaho、アメリカ、83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell、Idaho、アメリカ、83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene、Idaho、アメリカ、83814
- Kootenai Health - Coeur d'Alene
-
Emmett、Idaho、アメリカ、83617
- Walter Knox Memorial Hospital
-
Fruitland、Idaho、アメリカ、83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian、Idaho、アメリカ、83642
- Idaho Urologic Institute-Meridian
-
Meridian、Idaho、アメリカ、83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa、Idaho、アメリカ、83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa、Idaho、アメリカ、83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls、Idaho、アメリカ、83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint、Idaho、アメリカ、83864
- Kootenai Clinic Cancer Services - Sandpoint
-
Twin Falls、Idaho、アメリカ、83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Alton、Illinois、アメリカ、62002
- OSF Saint Anthony's Health Center
-
Aurora、Illinois、アメリカ、60504
- Rush-Copley Medical Center
-
Bloomington、Illinois、アメリカ、61704
- Illinois CancerCare-Bloomington
-
Canton、Illinois、アメリカ、61520
- Illinois CancerCare-Canton
-
Carbondale、Illinois、アメリカ、62902
- Memorial Hospital of Carbondale
-
Carterville、Illinois、アメリカ、62918
- SIH Cancer Institute
-
Carthage、Illinois、アメリカ、62321
- Illinois CancerCare-Carthage
-
Centralia、Illinois、アメリカ、62801
- Centralia Oncology Clinic
-
Chicago、Illinois、アメリカ、60637
- University of Chicago Comprehensive Cancer Center
-
Chicago、Illinois、アメリカ、60612
- John H Stroger Jr Hospital of Cook County
-
Chicago、Illinois、アメリカ、60612
- Rush MD Anderson Cancer Center
-
Danville、Illinois、アメリカ、61832
- Carle at The Riverfront
-
Decatur、Illinois、アメリカ、62526
- Decatur Memorial Hospital
-
Decatur、Illinois、アメリカ、62526
- Cancer Care Specialists of Illinois - Decatur
-
Dixon、Illinois、アメリカ、61021
- Illinois CancerCare-Dixon
-
Effingham、Illinois、アメリカ、62401
- Crossroads Cancer Center
-
Effingham、Illinois、アメリカ、62401
- Carle Physician Group-Effingham
-
Eureka、Illinois、アメリカ、61530
- Illinois CancerCare-Eureka
-
Evanston、Illinois、アメリカ、60201
- NorthShore University HealthSystem-Evanston Hospital
-
Galesburg、Illinois、アメリカ、61401
- Western Illinois Cancer Treatment Center
-
Galesburg、Illinois、アメリカ、61401
- Illinois CancerCare-Galesburg
-
Geneva、Illinois、アメリカ、60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview、Illinois、アメリカ、60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Harvey、Illinois、アメリカ、60426
- Ingalls Memorial Hospital
-
Highland Park、Illinois、アメリカ、60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Hinsdale、Illinois、アメリカ、60521
- Sudarshan K Sharma MD Limited-Gynecologic Oncology
-
Kewanee、Illinois、アメリカ、61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb、Illinois、アメリカ、61455
- Illinois CancerCare-Macomb
-
Mattoon、Illinois、アメリカ、61938
- Carle Physician Group-Mattoon/Charleston
-
Mount Vernon、Illinois、アメリカ、62864
- SSM Health Good Samaritan
-
New Lenox、Illinois、アメリカ、60451
- UC Comprehensive Cancer Center at Silver Cross
-
O'Fallon、Illinois、アメリカ、62269
- Cancer Care Center of O'Fallon
-
Orland Park、Illinois、アメリカ、60462
- University of Chicago Medicine-Orland Park
-
Ottawa、Illinois、アメリカ、61350
- Illinois CancerCare-Ottawa Clinic
-
Pekin、Illinois、アメリカ、61554
- Illinois CancerCare-Pekin
-
Peoria、Illinois、アメリカ、61636
- Methodist Medical Center of Illinois
-
Peoria、Illinois、アメリカ、61615
- Illinois CancerCare-Peoria
-
Peru、Illinois、アメリカ、61354
- Illinois CancerCare-Peru
-
Peru、Illinois、アメリカ、61354
- Valley Radiation Oncology
-
Princeton、Illinois、アメリカ、61356
- Illinois CancerCare-Princeton
-
Springfield、Illinois、アメリカ、62702
- Southern Illinois University School of Medicine
-
Springfield、Illinois、アメリカ、62702
- Springfield Clinic
-
Springfield、Illinois、アメリカ、62781
- Springfield Memorial Hospital
-
Urbana、Illinois、アメリカ、61801
- Carle Cancer Center
-
Urbana、Illinois、アメリカ、61801
- The Carle Foundation Hospital
-
Warrenville、Illinois、アメリカ、60555
- Northwestern Medicine Cancer Center Warrenville
-
Washington、Illinois、アメリカ、61571
- Illinois CancerCare - Washington
-
Yorkville、Illinois、アメリカ、60560
- Rush-Copley Healthcare Center
-
Zion、Illinois、アメリカ、60099
- Midwestern Regional Medical Center
-
-
Indiana
-
South Bend、Indiana、アメリカ、46601
- Memorial Hospital of South Bend
-
-
Iowa
-
Ames、Iowa、アメリカ、50010
- Mary Greeley Medical Center
-
Ames、Iowa、アメリカ、50010
- McFarland Clinic - Ames
-
Boone、Iowa、アメリカ、50036
- McFarland Clinic - Boone
-
Cedar Rapids、Iowa、アメリカ、52403
- Mercy Hospital
-
Cedar Rapids、Iowa、アメリカ、52403
- Oncology Associates at Mercy Medical Center
-
Clive、Iowa、アメリカ、50325
- Mercy Cancer Center-West Lakes
-
Clive、Iowa、アメリカ、50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Council Bluffs、Iowa、アメリカ、51503
- Alegent Health Mercy Hospital
-
Creston、Iowa、アメリカ、50801
- Greater Regional Medical Center
-
Des Moines、Iowa、アメリカ、50314
- Mercy Medical Center - Des Moines
-
Des Moines、Iowa、アメリカ、50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Fort Dodge、Iowa、アメリカ、50501
- McFarland Clinic - Trinity Cancer Center
-
Iowa City、Iowa、アメリカ、52242
- University of Iowa/Holden Comprehensive Cancer Center
-
Jefferson、Iowa、アメリカ、50129
- McFarland Clinic - Jefferson
-
Marshalltown、Iowa、アメリカ、50158
- McFarland Clinic - Marshalltown
-
West Des Moines、Iowa、アメリカ、50266
- Mercy Medical Center-West Lakes
-
-
Kansas
-
Garden City、Kansas、アメリカ、67846
- Central Care Cancer Center - Garden City
-
Great Bend、Kansas、アメリカ、67530
- Central Care Cancer Center - Great Bend
-
-
Kentucky
-
Bardstown、Kentucky、アメリカ、40004
- CommonSpirit Saint Joseph Hospital - Bardstown
-
Corbin、Kentucky、アメリカ、40701
- Commonwealth Cancer Center-Corbin
-
Lexington、Kentucky、アメリカ、40504
- Saint Joseph Radiation Oncology Resource Center
-
Lexington、Kentucky、アメリカ、40509
- CommonSpirit Saint Joseph Medical Center - East Lexington
-
London、Kentucky、アメリカ、40741
- CommonSpirit Saint Joseph Hospital London
-
Louisville、Kentucky、アメリカ、40202
- Jewish Hospital
-
Louisville、Kentucky、アメリカ、40245
- UofL Health Medical Center Northeast
-
Louisville、Kentucky、アメリカ、40215
- Saints Mary and Elizabeth Hospital
-
Shepherdsville、Kentucky、アメリカ、40165
- Jewish Hospital Medical Center South
-
-
Louisiana
-
Baton Rouge、Louisiana、アメリカ、70817
- Our Lady of the Lake Medical Oncology
-
-
Maine
-
Augusta、Maine、アメリカ、04330
- Harold Alfond Center for Cancer Care
-
Brewer、Maine、アメリカ、04412
- Lafayette Family Cancer Center-EMMC
-
Scarborough、Maine、アメリカ、04074
- MaineHealth Maine Medical Center- Scarborough
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21204
- Greater Baltimore Medical Center
-
Bethesda、Maryland、アメリカ、20892
- National Institutes of Health Clinical Center
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48109
- University of Michigan Rogel Cancer Center
-
Dearborn、Michigan、アメリカ、48124
- Corewell Health Dearborn Hospital
-
Royal Oak、Michigan、アメリカ、48073
- Corewell Health William Beaumont University Hospital
-
Troy、Michigan、アメリカ、48085
- Corewell Health Beaumont Troy Hospital
-
-
Minnesota
-
Burnsville、Minnesota、アメリカ、55337
- Fairview Ridges Hospital
-
Burnsville、Minnesota、アメリカ、55337
- Minnesota Oncology - Burnsville
-
Cambridge、Minnesota、アメリカ、55008
- Cambridge Medical Center
-
Coon Rapids、Minnesota、アメリカ、55433
- Mercy Hospital
-
Edina、Minnesota、アメリカ、55435
- Fairview Southdale Hospital
-
Fridley、Minnesota、アメリカ、55432
- Unity Hospital
-
Maple Grove、Minnesota、アメリカ、55369
- Fairview Clinics and Surgery Center Maple Grove
-
Maplewood、Minnesota、アメリカ、55109
- Saint John's Hospital - Healtheast
-
Maplewood、Minnesota、アメリカ、55109
- Minnesota Oncology Hematology PA-Maplewood
-
Minneapolis、Minnesota、アメリカ、55415
- Hennepin County Medical Center
-
Minneapolis、Minnesota、アメリカ、55407
- Abbott-Northwestern Hospital
-
Minneapolis、Minnesota、アメリカ、55454
- Health Partners Inc
-
Minneapolis、Minnesota、アメリカ、55455
- University of Minnesota/Masonic Cancer Center
-
Monticello、Minnesota、アメリカ、55362
- Monticello Cancer Center
-
New Ulm、Minnesota、アメリカ、56073
- New Ulm Medical Center
-
Princeton、Minnesota、アメリカ、55371
- Fairview Northland Medical Center
-
Robbinsdale、Minnesota、アメリカ、55422
- North Memorial Medical Health Center
-
Saint Louis Park、Minnesota、アメリカ、55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul、Minnesota、アメリカ、55101
- Regions Hospital
-
Saint Paul、Minnesota、アメリカ、55102
- United Hospital
-
Shakopee、Minnesota、アメリカ、55379
- Saint Francis Regional Medical Center
-
Stillwater、Minnesota、アメリカ、55082
- Lakeview Hospital
-
Waconia、Minnesota、アメリカ、55387
- Ridgeview Medical Center
-
Willmar、Minnesota、アメリカ、56201
- Rice Memorial Hospital
-
Woodbury、Minnesota、アメリカ、55125
- Minnesota Oncology Hematology PA-Woodbury
-
Wyoming、Minnesota、アメリカ、55092
- Fairview Lakes Medical Center
-
-
Missouri
-
Ballwin、Missouri、アメリカ、63011
- Mercy Oncology and Hematology - Clayton-Clarkson
-
Bolivar、Missouri、アメリカ、65613
- Central Care Cancer Center - Bolivar
-
Cape Girardeau、Missouri、アメリカ、63703
- Saint Francis Medical Center
-
Cape Girardeau、Missouri、アメリカ、63703
- Mercy Cancer Center - Cape Girardeau
-
Farmington、Missouri、アメリカ、63640
- Parkland Health Center - Farmington
-
Jefferson City、Missouri、アメリカ、65109
- MU Health Care Goldschmidt Cancer Center
-
Joplin、Missouri、アメリカ、64804
- Freeman Health System
-
Joplin、Missouri、アメリカ、64804
- Mercy Hospital Joplin
-
Rolla、Missouri、アメリカ、65401
- Mercy Clinic-Rolla-Cancer and Hematology
-
Rolla、Missouri、アメリカ、65401
- Phelps Health Delbert Day Cancer Institute
-
Saint Joseph、Missouri、アメリカ、64506
- Heartland Regional Medical Center
-
Sainte Genevieve、Missouri、アメリカ、63670
- Sainte Genevieve County Memorial Hospital
-
Springfield、Missouri、アメリカ、65807
- CoxHealth South Hospital
-
Springfield、Missouri、アメリカ、65804
- Mercy Hospital Springfield
-
St Louis、Missouri、アメリカ、63110
- Washington University School of Medicine
-
St Louis、Missouri、アメリカ、63131
- Missouri Baptist Medical Center
-
St Louis、Missouri、アメリカ、63109
- Mercy Infusion Center - Chippewa
-
St Louis、Missouri、アメリカ、63141
- Mercy Hospital Saint Louis
-
St Louis、Missouri、アメリカ、63128
- Mercy Hospital South
-
Sullivan、Missouri、アメリカ、63080
- Missouri Baptist Sullivan Hospital
-
Washington、Missouri、アメリカ、63090
- Mercy Hospital Washington
-
-
Montana
-
Anaconda、Montana、アメリカ、59711
- Community Hospital of Anaconda
-
Billings、Montana、アメリカ、59101
- Billings Clinic Cancer Center
-
Bozeman、Montana、アメリカ、59715
- Bozeman Health Deaconess Hospital
-
Great Falls、Montana、アメリカ、59405
- Great Falls Clinic
-
Great Falls、Montana、アメリカ、59405
- Benefis Sletten Cancer Institute
-
Kalispell、Montana、アメリカ、59901
- Logan Health Medical Center
-
Missoula、Montana、アメリカ、59802
- Saint Patrick Hospital - Community Hospital
-
Missoula、Montana、アメリカ、59804
- Community Medical Center
-
-
Nebraska
-
Grand Island、Nebraska、アメリカ、68803
- Nebraska Cancer Specialists/Oncology Hematology West PC
-
Kearney、Nebraska、アメリカ、68847
- CHI Health Good Samaritan
-
Lincoln、Nebraska、アメリカ、68510
- Saint Elizabeth Regional Medical Center
-
Lincoln、Nebraska、アメリカ、68516
- Cancer Partners of Nebraska
-
Omaha、Nebraska、アメリカ、68114
- Nebraska Methodist Hospital
-
Omaha、Nebraska、アメリカ、68198
- University of Nebraska Medical Center
-
Omaha、Nebraska、アメリカ、68124
- Alegent Health Bergan Mercy Medical Center
-
Omaha、Nebraska、アメリカ、68122
- Alegent Health Immanuel Medical Center
-
Omaha、Nebraska、アメリカ、68130
- Alegent Health Lakeside Hospital
-
Papillion、Nebraska、アメリカ、68046
- Midlands Community Hospital
-
-
Nevada
-
Las Vegas、Nevada、アメリカ、89106
- Women's Cancer Center of Nevada
-
-
New Jersey
-
Neptune City、New Jersey、アメリカ、07753
- Jersey Shore Medical Center
-
-
New Mexico
-
Albuquerque、New Mexico、アメリカ、87106
- University of New Mexico Cancer Center
-
Las Cruces、New Mexico、アメリカ、88011
- Memorial Medical Center-Las Cruces
-
Rio Rancho、New Mexico、アメリカ、87124
- Presbyterian Rust Medical Center/Jorgensen Cancer Center
-
-
New York
-
Bay Shore、New York、アメリカ、11706
- Northwell Health Imbert Cancer Center
-
Brightwaters、New York、アメリカ、11718
- Island Gynecologic Oncology
-
Buffalo、New York、アメリカ、14263
- Roswell Park Cancer Institute
-
Lake Success、New York、アメリカ、11042
- Northwell Health/Center for Advanced Medicine
-
Syracuse、New York、アメリカ、13210
- State University of New York Upstate Medical University
-
White Plains、New York、アメリカ、10601
- Dickstein Cancer Treatment Center
-
-
North Carolina
-
Clinton、North Carolina、アメリカ、28328
- Southeastern Medical Oncology Center-Clinton
-
Goldsboro、North Carolina、アメリカ、27534
- Southeastern Medical Oncology Center-Goldsboro
-
Jacksonville、North Carolina、アメリカ、28546
- Southeastern Medical Oncology Center-Jacksonville
-
-
Ohio
-
Akron、Ohio、アメリカ、44304
- Summa Health System - Akron Campus
-
Alliance、Ohio、アメリカ、44601
- Aultman Alliance Community Hospital
-
Beachwood、Ohio、アメリカ、44122
- UHHS-Chagrin Highlands Medical Center
-
Belpre、Ohio、アメリカ、45714
- Strecker Cancer Center-Belpre
-
Canton、Ohio、アメリカ、44710
- Aultman Health Foundation
-
Centerville、Ohio、アメリカ、45459
- Miami Valley Hospital South
-
Chardon、Ohio、アメリカ、44024
- Geauga Hospital
-
Chillicothe、Ohio、アメリカ、45601
- Adena Regional Medical Center
-
Cincinnati、Ohio、アメリカ、45220
- Good Samaritan Hospital - Cincinnati
-
Cincinnati、Ohio、アメリカ、45242
- Bethesda North Hospital
-
Cincinnati、Ohio、アメリカ、45247
- TriHealth Cancer Institute-Westside
-
Cincinnati、Ohio、アメリカ、45255
- TriHealth Cancer Institute-Anderson
-
Cleveland、Ohio、アメリカ、44106
- Case Western Reserve University
-
Cleveland、Ohio、アメリカ、44195
- Cleveland Clinic Foundation
-
Cleveland、Ohio、アメリカ、44111
- Cleveland Clinic Cancer Center/Fairview Hospital
-
Columbus、Ohio、アメリカ、43214
- Riverside Methodist Hospital
-
Columbus、Ohio、アメリカ、43210
- Ohio State University Comprehensive Cancer Center
-
Columbus、Ohio、アメリカ、43219
- The Mark H Zangmeister Center
-
Columbus、Ohio、アメリカ、43214
- Columbus Oncology and Hematology Associates Inc
-
Columbus、Ohio、アメリカ、43228
- Doctors Hospital
-
Columbus、Ohio、アメリカ、43213
- Mount Carmel East Hospital
-
Columbus、Ohio、アメリカ、43215
- Grant Medical Center
-
Columbus、Ohio、アメリカ、43222
- Mount Carmel Health Center West
-
Dayton、Ohio、アメリカ、45409
- Miami Valley Hospital
-
Delaware、Ohio、アメリカ、43015
- Delaware Health Center-Grady Cancer Center
-
Delaware、Ohio、アメリカ、43015
- Grady Memorial Hospital
-
Dublin、Ohio、アメリカ、43016
- Dublin Methodist Hospital
-
Gahanna、Ohio、アメリカ、43230
- Central Ohio Breast and Endocrine Surgery
-
Grove City、Ohio、アメリカ、43123
- Mount Carmel Grove City Hospital
-
Lancaster、Ohio、アメリカ、43130
- Fairfield Medical Center
-
Lima、Ohio、アメリカ、45801
- Saint Rita's Medical Center
-
Mansfield、Ohio、アメリカ、44903
- OhioHealth Mansfield Hospital
-
Marietta、Ohio、アメリカ、45750
- Marietta Memorial Hospital
-
Marion、Ohio、アメリカ、43302
- OhioHealth Marion General Hospital
-
Mayfield Heights、Ohio、アメリカ、44124
- Hillcrest Hospital Cancer Center
-
Mentor、Ohio、アメリカ、44060
- UH Seidman Cancer Center at Lake Health Mentor Campus
-
Mount Vernon、Ohio、アメリカ、43050
- Knox Community Hospital
-
Newark、Ohio、アメリカ、43055
- Licking Memorial Hospital
-
Newark、Ohio、アメリカ、43055
- Newark Radiation Oncology
-
Perrysburg、Ohio、アメリカ、43551
- Mercy Health - Perrysburg Hospital
-
Portsmouth、Ohio、アメリカ、45662
- Southern Ohio Medical Center
-
Toledo、Ohio、アメリカ、43623
- Mercy Health - Saint Anne Hospital
-
Toledo、Ohio、アメリカ、43608
- Mercy Health - Saint Vincent Hospital
-
Wadsworth、Ohio、アメリカ、44281
- University Hospitals Sharon Health Center
-
Westerville、Ohio、アメリカ、43081
- Saint Ann's Hospital
-
Westlake、Ohio、アメリカ、44145
- UH Seidman Cancer Center at Saint John Medical Center
-
Zanesville、Ohio、アメリカ、43701
- Genesis Healthcare System Cancer Care Center
-
-
Oklahoma
-
Lawton、Oklahoma、アメリカ、73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City、Oklahoma、アメリカ、73104
- University of Oklahoma Health Sciences Center
-
Oklahoma City、Oklahoma、アメリカ、73120
- Mercy Hospital Oklahoma City
-
Tulsa、Oklahoma、アメリカ、74146
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
-
Oregon
-
Baker City、Oregon、アメリカ、97814
- Saint Alphonsus Cancer Care Center-Baker City
-
Bend、Oregon、アメリカ、97701
- Saint Charles Health System
-
Clackamas、Oregon、アメリカ、97015
- Clackamas Radiation Oncology Center
-
Clackamas、Oregon、アメリカ、97015
- Providence Cancer Institute Clackamas Clinic
-
Coos Bay、Oregon、アメリカ、97420
- Bay Area Hospital
-
Newberg、Oregon、アメリカ、97132
- Providence Newberg Medical Center
-
Ontario、Oregon、アメリカ、97914
- Saint Alphonsus Cancer Care Center-Ontario
-
Portland、Oregon、アメリカ、97210
- Legacy Good Samaritan Hospital and Medical Center
-
Portland、Oregon、アメリカ、97213
- Providence Portland Medical Center
-
Portland、Oregon、アメリカ、97225
- Providence Saint Vincent Medical Center
-
Redmond、Oregon、アメリカ、97756
- Saint Charles Health System-Redmond
-
Tualatin、Oregon、アメリカ、97062
- Legacy Meridian Park Hospital
-
-
Pennsylvania
-
Butler、Pennsylvania、アメリカ、16001
- UPMC Hillman Cancer Center at Butler Health System
-
Erie、Pennsylvania、アメリカ、16505
- UPMC Hillman Cancer Center Erie
-
Paoli、Pennsylvania、アメリカ、19301
- Paoli Memorial Hospital
-
Philadelphia、Pennsylvania、アメリカ、19107
- Thomas Jefferson University Hospital
-
Philadelphia、Pennsylvania、アメリカ、19114
- Jefferson Torresdale Hospital
-
Pittsburgh、Pennsylvania、アメリカ、15224
- West Penn Hospital
-
Pittsburgh、Pennsylvania、アメリカ、15232
- UPMC Hillman Cancer Center
-
Pittsburgh、Pennsylvania、アメリカ、15213
- UPMC-Magee Womens Hospital
-
Pittsburgh、Pennsylvania、アメリカ、15237
- UPMC-Passavant Hospital
-
Willow Grove、Pennsylvania、アメリカ、19090
- Asplundh Cancer Pavilion
-
Wynnewood、Pennsylvania、アメリカ、19096
- Lankenau Medical Center
-
-
Rhode Island
-
Providence、Rhode Island、アメリカ、02905
- Women and Infants Hospital
-
-
South Carolina
-
Charleston、South Carolina、アメリカ、29425
- Medical University of South Carolina
-
Greenville、South Carolina、アメリカ、29607
- Saint Francis Cancer Center
-
Greenville、South Carolina、アメリカ、29601
- Saint Francis Hospital
-
-
South Dakota
-
Rapid City、South Dakota、アメリカ、57701
- Rapid City Regional Hospital
-
-
Tennessee
-
Bristol、Tennessee、アメリカ、37620
- Bristol Regional Medical Center
-
Kingsport、Tennessee、アメリカ、37660
- Ballad Health Cancer Care - Kingsport
-
Kingsport、Tennessee、アメリカ、37660
- Wellmont Holston Valley Hospital and Medical Center
-
Knoxville、Tennessee、アメリカ、37916
- Covenant Health Cancer Centers
-
Knoxville、Tennessee、アメリカ、37932
- Covenant Health Cancer Centers - West
-
Nashville、Tennessee、アメリカ、37232
- Vanderbilt University/Ingram Cancer Center
-
Nashville、Tennessee、アメリカ、37204
- Vanderbilt Breast Center at One Hundred Oaks
-
-
Texas
-
Bryan、Texas、アメリカ、77802
- Saint Joseph Regional Cancer Center
-
Dallas、Texas、アメリカ、75235
- Parkland Memorial Hospital
-
Dallas、Texas、アメリカ、75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Houston、Texas、アメリカ、77030
- Houston Methodist Hospital
-
Houston、Texas、アメリカ、77070
- Methodist Willowbrook Hospital
-
Houston、Texas、アメリカ、77094
- Houston Methodist West Hospital
-
Sugar Land、Texas、アメリカ、77479
- Houston Methodist Sugar Land Hospital
-
The Woodlands、Texas、アメリカ、77385
- Houston Methodist The Woodlands Hospital
-
-
Virginia
-
Bristol、Virginia、アメリカ、24201
- Ballad Health Cancer Care - Bristol
-
Norton、Virginia、アメリカ、24273
- Ballad Health Cancer Care - Norton
-
-
Washington
-
Aberdeen、Washington、アメリカ、98520
- Providence Regional Cancer System-Aberdeen
-
Bellingham、Washington、アメリカ、98225
- PeaceHealth Saint Joseph Medical Center
-
Burien、Washington、アメリカ、98166
- Saint Anne Hospital
-
Centralia、Washington、アメリカ、98531
- Providence Regional Cancer System-Centralia
-
Edmonds、Washington、アメリカ、98026
- Swedish Cancer Institute-Edmonds
-
Enumclaw、Washington、アメリカ、98022
- Saint Elizabeth Hospital
-
Everett、Washington、アメリカ、98201
- Providence Regional Cancer Partnership
-
Federal Way、Washington、アメリカ、98003
- Saint Francis Hospital
-
Issaquah、Washington、アメリカ、98029
- Swedish Cancer Institute-Issaquah
-
Kennewick、Washington、アメリカ、99336
- Kadlec Clinic Hematology and Oncology
-
Lacey、Washington、アメリカ、98503
- Providence Regional Cancer System-Lacey
-
Lakewood、Washington、アメリカ、98499
- Saint Clare Hospital
-
Longview、Washington、アメリカ、98632
- PeaceHealth Saint John Medical Center
-
Port Townsend、Washington、アメリカ、98368
- Jefferson Healthcare
-
Seattle、Washington、アメリカ、98107
- Swedish Medical Center-Ballard Campus
-
Seattle、Washington、アメリカ、98122
- Swedish Medical Center-First Hill
-
Seattle、Washington、アメリカ、98104
- Pacific Gynecology Specialists
-
Seattle、Washington、アメリカ、98122-5711
- Swedish Medical Center-Cherry Hill
-
Sedro-Woolley、Washington、アメリカ、98284
- PeaceHealth United General Medical Center
-
Shelton、Washington、アメリカ、98584
- Providence Regional Cancer System-Shelton
-
Silverdale、Washington、アメリカ、98383
- Saint Joseph Medical Center Hematology and Oncology - Silverdale
-
Tacoma、Washington、アメリカ、98405
- Franciscan Research Center-Northwest Medical Plaza
-
Vancouver、Washington、アメリカ、98686
- Legacy Salmon Creek Hospital
-
Vancouver、Washington、アメリカ、98664
- PeaceHealth Southwest Medical Center
-
Walla Walla、Washington、アメリカ、99362
- Providence Saint Mary Regional Cancer Center
-
Yelm、Washington、アメリカ、98597
- Providence Regional Cancer System-Yelm
-
-
West Virginia
-
Charleston、West Virginia、アメリカ、25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
-
Wisconsin
-
Green Bay、Wisconsin、アメリカ、54301
- Saint Vincent Hospital Cancer Center Green Bay
-
Green Bay、Wisconsin、アメリカ、54303
- Saint Vincent Hospital Cancer Center at Saint Mary's
-
La Crosse、Wisconsin、アメリカ、54601
- Gundersen Lutheran Medical Center
-
Milwaukee、Wisconsin、アメリカ、53226
- Medical College of Wisconsin
-
Mukwonago、Wisconsin、アメリカ、53149
- ProHealth D N Greenwald Center
-
New Richmond、Wisconsin、アメリカ、54017
- Cancer Center of Western Wisconsin
-
Oconomowoc、Wisconsin、アメリカ、53066
- ProHealth Oconomowoc Memorial Hospital
-
Oconto Falls、Wisconsin、アメリカ、54154
- Saint Vincent Hospital Cancer Center at Oconto Falls
-
Sturgeon Bay、Wisconsin、アメリカ、54235-1495
- Saint Vincent Hospital Cancer Center at Sturgeon Bay
-
Waukesha、Wisconsin、アメリカ、53188
- UW Cancer Center at ProHealth Care
-
Waukesha、Wisconsin、アメリカ、53188
- ProHealth Waukesha Memorial Hospital
-
-
Wyoming
-
Cody、Wyoming、アメリカ、82414
- Billings Clinic-Cody
-
Sheridan、Wyoming、アメリカ、82801
- Welch Cancer Center
-
-
-
-
-
Bayamón、プエルトリコ、00959-5060
- Cancer Center-Metro Medical Center Bayamon
-
Caguas、プエルトリコ、00726
- HIMA San Pablo Oncologic Hospital
-
Manati、プエルトリコ、00674
- Doctors Cancer Center
-
Ponce、プエルトリコ、00716
- Instituto Oncologia Moderna Ponce
-
San Juan、プエルトリコ、00917
- San Juan Community Oncology Group
-
San Juan、プエルトリコ、00927
- Centro Comprensivo de Cancer de UPR
-
San Juan、プエルトリコ、00936
- San Juan City Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Women with recurrent/persistent platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers; platinum-resistant disease is defined as progression within < 6 months from completion of platinum based therapy. The date should be calculated from the last administered dose of platinum therapy
-
Patients must have histologically or cytologically confirmed ovarian cancer, peritoneal cancer or fallopian tube cancer and must have a histological diagnosis of high grade serous, grade 3 endometrioid or clear cell carcinoma based on local histopathological findings. Patients with low grade serous, grade 1 or 2 endometrioid, mixed epithelial, undifferentiated carcinoma, or mucinous carcinoma histologies are also eligible, provided that the patient has a known deleterious BRCA1 or BRCA2 mutation identified through testing at a clinical laboratory. Histologic confirmation of the original primary tumor is required via the pathology report (upload of report required). Confirmation of BRCA1 and BRCA2 germline and/or somatic mutation status and hormone receptor (HR) status is required for all entered patients (if available) via testing report (upload of report[s] required)
-
Evaluable disease - defined as RECIST 1.1 measurable disease OR non-measurable disease (defined as solid and/or cystic abnormalities on radiographic imaging that do not meet RECIST 1.1 definitions for target lesions OR ascites and/or pleural effusion that has been pathologically demonstrated to be disease-related in the setting of a CA125 >= 2 x upper limit of normal [ULN])
-
Prior therapy:
- At least two prior treatment regimens (including primary therapy) but up to 5 lines of systemic anticancer therapy. Hormonal therapy (such as tamoxifen, aromatase inhibitors) will not count as a previous treatment regimen.
- Prior use of bevacizumab in the upfront or recurrent setting is required.
- Prior use of PARP inhibitor is allowed.
- Prior use of immune checkpoint blockade (e.g., a PD-L1/PD-1inhibitor or a CTLA-4 inhibitor) is allowed
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
-
Absolute neutrophil count (ANC) >= 1,500/mcL
-
Hemoglobin >= 10 g/dL
-
Platelets >= 100,000/mcL
-
Creatinine clearance (CrCL) or estimated glomerular filtration rate (eGFR) of > 50 mL/min estimated using either the Cockcroft-Gault equation, the Modification of Diet in Renal Disease Study, or as reported in the comprehensive metabolic panel/basic metabolic panel (eGFR)
-
Urine protein: creatinine ratio (UPC) of =< 1
-
Total serum bilirubin level =< 1.5 x ULN (patients with known Gilbert's disease who have bilirubin level =< 3 x ULN may be enrolled)
-
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN
-
Age >= 18 years
-
Body weight > 30 kg
-
Adequately controlled blood pressure (systolic blood pressure [SBP] =< 140; diastolic blood pressure [DBP] =< 90 mmHg) on a maximum of three antihypertensive medications. Patients must have a BP of =< 140/90 mmHg taken in the clinic setting by a medical professional within 2 weeks prior to study registration. It is strongly recommended that patients who are on three antihypertensive medications be followed by a cardiologist or a primary care physician for management of BP while on protocol. Patients must be willing and able to check and record daily blood pressure readings. BP cuffs will be provided to patients randomized to the cediranib-containing arms
-
Adequately controlled thyroid dysfunction with no symptoms of thyroid dysfunction and normal thyroid stimulating hormone (TSH). If TSH is not within normal range despite no symptoms of thyroid dysfunction, normal free T4 level is required
-
Able to swallow and retain oral medications and no gastrointestinal (GI) illnesses that would preclude absorption of olaparib and cediranib as judged by treating physician
-
Toxicities of prior therapy (excepting alopecia and vitiligo), should be resolved to less than or equal to grade 1 as per Common Terminology Criteria for Adverse Events (CTCAE) v5.0
-
Women of childbearing potential (WOCBP) must agree to use two forms of birth control (hormonal or barrier method of birth control; abstinence). Note: Definition of women of no longer having childbearing potential: Postmenopausal or evidence of non-childbearing status for women of childbearing potential as confirmed by a negative urine or serum pregnancy test within 7 days prior to start of study treatment. Postmenopausal is defined as: Age >= 60 years, or age < 60 with any one or more of the conditions below:
- Amenorrhoeic for >= 1 year in the absence of chemotherapy and/or hormonal treatments,
- Luteinizing hormone and/or follicle stimulating hormone and/or estradiol levels in the post-menopausal range,
- Radiation-induced oophorectomy with last menses > 1 year ago,
- Chemotherapy-induced menopause with > 1 year interval since last menses,
- Surgical sterilization (bilateral oophorectomy or hysterectomy)
-
The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and authorization permitting release of personal health information
Exclusion Criteria:
-
Primary platinum-refractory disease defined as progression during first-line platinum-based chemotherapy
-
Rising CA-125 only without RECIST 1.1 evaluable disease
-
Prior therapy:
-
Patients who have had chemotherapy, investigational drugs or radiotherapy within 3 weeks prior to study registration or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier.
-
Patients may not have had hormonal therapy within 2 weeks of study registration. Patients receiving raloxifene for bone health as per Food and Drug Administration (FDA) indication may remain on raloxifene absent other drug interactions.
-
Prior use of concurrent olaparib and cediranib combination.
-
Patients who have experienced immune-mediated adverse events requiring dose modification or discontinuation.
-
For patients who have received prior PARP inhibitor:
- Patients who have required dose modification or dose reduction of olaparib will not be eligible, as they will not be able to start this study at full dose.
- Patients who have required dose reduction of non-olaparib PARP inhibitors for hematologic adverse events will not be eligible (Note: niraparib that is initiated at 200mg daily per weight and platelet guidelines is not considered a dose reduction).
- Patients who required dose-reduction of non-olaparib PARP inhibitors for non-hematologic adverse events may be eligible after discussion with the Study Chair if the treating investigator feels that they could appropriately receive olaparib at full dose.
-
-
History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 3 months prior to study registration
-
Current signs and/or symptoms of bowel obstruction or signs and/or symptoms of bowel obstruction within 3 months of study registration except temporary (< 24 hr) improved with medical management, within last 3 months
-
Any prior grade >= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 1
-
Dependency on IV hydration or total parenteral nutrition (TPN)
-
Pregnant women. Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with these drugs, breastfeeding should be discontinued. These potential risks may also apply to other agents used in this study
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
-
Patients with untreated brain metastases, spinal cord compression, or evidence of symptomatic brain metastases or leptomeningeal disease as noted on computed tomography (CT) or magnetic resonance imaging (MRI) scans should not be included on this study, since neurologic dysfunction may confound the evaluation of neurologic and other adverse events. Patients with treated brain metastases and resolution of any associated symptoms must demonstrate stable post-therapeutic imaging for at least 6 months following therapy prior to starting study registration
-
Patients who have the following clinical conditions are considered to be at increased risk for cardiac toxicities. Patients with any cardiac history of the following conditions:
- History of myocardial infarction or myocarditis within six months of study registration
- Unstable angina
- Resting electrocardiogram (ECG) with clinically significant abnormal findings.
- New York Heart Association functional classification of III or IV
-
If cardiac function assessment is clinically indicated or performed: left ventricular ejection fraction (LVEF) less than normal per institutional guidelines, or < 55%, if threshold for normal not otherwise specified by institutional guidelines. Patients with the following risk factors should have a baseline cardiac function assessment:
- Prior treatment with anthracyclines
- Prior treatment with trastuzumab or T-DM1
- Prior central thoracic radiation therapy (RT), including RT to the heart
- History of myocardial infarction within 6 to 12 months (Patients with history of myocardial infarction within 6 months are excluded from the study)
- Prior history of impaired cardiac function
-
History of stroke or transient ischemic attack within six months of study registration
-
Clinically significant peripheral vascular disease or vascular disease (aortic aneurysm or aortic dissection)
-
Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of study treatment. Patients must have recovered from any effects of any major surgery and surgical wound should have healed prior to starting treatment. Note: Local surgery of isolated lesions for palliative intent is acceptable
-
Evidence of coagulopathy or bleeding diathesis. Therapeutic anticoagulation for prior thromboembolic events, including warfarin, is permitted. Patients receiving warfarin are recommended to have careful monitoring of international normalized ratio (INR)
-
Evidence suggestive of myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) on peripheral blood smear or bone marrow biopsy, if clinically indicated. No prior allogeneic bone marrow transplant or double umbilical cord blood transplantation (dUBCT)
-
Human immunodeficiency virus (HIV) positive patients due to potential drug and drug interactions
-
Patients may not use any complementary or alternative medicines including natural herbal products or folk remedies as they may interfere with the effectiveness of the study treatments
-
Receipt of live attenuated vaccine within 30 days prior to the first dose of study treatment. Note: Patients, if enrolled, should not receive live vaccine whilst receiving study treatment and up to 30 days after the last dose of study treatment
-
Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (other than atrial fibrillation with controlled ventricular rate), or psychiatric illness/social situations that would limit compliance with study requirements, substantially increase risk of incurring adverse events or compromise the ability of the patient to given written informed consent
-
Patients receiving any medications or substances that are strong inhibitors or inducers of CYP3A4. Dihydropyridine calcium-channel blockers are permitted for management of hypertension
-
Current or prior use of immunosuppressive medication within 14 days of study registration. The following are exceptions to this criterion:
- Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)
- Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent
- Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)
-
History of allergic reactions attributed to compounds of similar chemical or biologic composition to durvalumab, olaparib, or cediranib
-
Patients with active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment
-
Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis [TB] testing in line with local practice), hepatitis B (known positive hepatitis B virus [HBV] surface antigen (HBsAg) result), or hepatitis C. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for hepatitis C virus (HCV) ribonucleic acid (RNA)
-
Patients who have a history of (non-infectious) pneumonitis that required steroids, or current pneumonitis
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Arm I (paclitaxel, doxorubicin, topotecan hydrochloride))
Patients receive paclitaxel IV over 60 minutes on days 1, 8, and 15, or pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1, or topotecan hydrochloride IV over 30 minutes on days 1, 8 and 15 or days 1-5 per the discretion of the treating physician. Cycles repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial. |
Given IV
他の名前:
Undergo CT
他の名前:
Undergo MRI
他の名前:
Undergo ECHO
他の名前:
Undergo MUGA
他の名前:
Undergo collection of blood
他の名前:
Given IV
他の名前:
Given IV
他の名前:
Undergo CT with contrast
他の名前:
|
|
実験的:Arm II (durvalumab, cediranib maleate, olaparib)
Patients receive durvalumab IV over 60 minutes on day 1, cediranib maleate PO QD Monday through Friday, and olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial. |
Undergo CT
他の名前:
Undergo MRI
他の名前:
Undergo ECHO
他の名前:
Undergo MUGA
他の名前:
Undergo collection of blood
他の名前:
Given PO
他の名前:
Given PO
他の名前:
Undergo CT with contrast
他の名前:
Given IV
他の名前:
|
|
実験的:Arm III (durvalumab, cediranib maleate)
Patients receive durvalumab IV over 60 minutes on day 1 and cediranib maleate PO QD Monday through Friday. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial. |
Undergo CT
他の名前:
Undergo MRI
他の名前:
Undergo ECHO
他の名前:
Undergo MUGA
他の名前:
Undergo collection of blood
他の名前:
Given PO
他の名前:
Undergo CT with contrast
他の名前:
Given IV
他の名前:
|
|
実験的:Arm IV (cediranib maleate, olaparib)
Patients receive cediranib maleate PO QD on days 1-28 and olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial. |
Undergo CT
他の名前:
Undergo MRI
他の名前:
Undergo ECHO
他の名前:
Undergo collection of blood
他の名前:
Given PO
他の名前:
Given PO
他の名前:
Undergo CT with contrast
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression Free Survival
時間枠:From start of treatment to time of progression or death, whichever occurs first. Median follow-up time was 4.8 months (Inter-Quartile Range: 2.0-7.9 months).
|
The relationship of randomized treatment assignment to progression free survival. The RECIST 1.1 criteria are used for disease progression. Progression is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). |
From start of treatment to time of progression or death, whichever occurs first. Median follow-up time was 4.8 months (Inter-Quartile Range: 2.0-7.9 months).
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Objective Response Rate
時間枠:From the start of the treatment until disease progression/recurrence, or termination by the DMC. The median followup time was 4.3 months. The maximum followup time was 11 months. Patients are no longer being assessed.
|
Determination of response should take into consideration all target and non-target lesions. Here are the definitions of CR, PR, PD and SD: Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters (i.e. the nadir) while on study. The CI is the Jeffreys interval. |
From the start of the treatment until disease progression/recurrence, or termination by the DMC. The median followup time was 4.3 months. The maximum followup time was 11 months. Patients are no longer being assessed.
|
|
Duration of Response
時間枠:Throughout study treatment, up to 10.6 months.
|
Tumor response was assessed using Response Evaluation Criteria In Solid Tumors Criteria (RECIST 1.1) criteria. Duration of response was defined as the time from the first documentation of objective tumor response (complete response (CR) or partial response (PR)) to the first documented progressive disease (PD), or to death due to any cause, whichever occurs first. Per RECIST, Complete Response (CR) is defined as the disappearance of all target lesions; Partial Response (PR) is defined as an >=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD) is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Reporting the number of months from complete or partial response until disease progression, death or censoring, whichever occurs first. In the absence of disease progression or death, censoring time is based on date of last CT scan. |
Throughout study treatment, up to 10.6 months.
|
|
Overall Survival
時間枠:Time from study entry to date of death from any cause, or termination by the DMC. The median followup time was 4.3 months. The maximum followup time was 11 months. Patients are no longer being assessed.
|
Overall survival will be presented by Kaplan Meier methods. Overall Survival (OS) is defined as the duration of time from study entry to date of death from any cause. A subject who has not died will be censored on the date that they were last known to be alive. |
Time from study entry to date of death from any cause, or termination by the DMC. The median followup time was 4.3 months. The maximum followup time was 11 months. Patients are no longer being assessed.
|
|
Count of Participants With a Grade 3 (or Higher) Adverse Event
時間枠:From the start of treatment until disease progression/recurrence or termination by the DMC. The median followup time was 4.3 months. The maximum followup time was 11 months. Patients are no longer being assessed.
|
The number of patients (in each reporting group) who experienced a grade 3 (or higher) adverse event |
From the start of treatment until disease progression/recurrence or termination by the DMC. The median followup time was 4.3 months. The maximum followup time was 11 months. Patients are no longer being assessed.
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- アミノ酸、ペプチド、およびタンパク質
- タンパク質
- 硫黄化合物
- 有機化学物質
- 複素環化化合物
- 調査手法
- 臨床検査技術
- 診断技術と手順
- 診断
- 薬理学的行動
- 化学作用と用途
- 炭化水素
- シクロパラフィン
- 炭化水素、環状
- 炭化水素、周期的
- テルペン
- 炭水化物
- カムプトテシン
- アルカロイド
- 多環芳香族炭化水素
- 炭化水素、芳香
- 多環式化合物
- グリコシド
- 抗体
- 免疫グロブリン
- 免疫タンパク質
- 血液タンパク質
- 血清グロブリン
- グロブリン
- 無機化学物質
- タキソイド
- シクロデカン
- Diterpenes
- ヘルスケアの経済学と組織
- 化学物質の専門用途
- 化学技術、分析
- スペクトル分析
- アントラサイクリン
- ナフテセン
- アミノグリコシド
- 免疫グロブリンアイソタイプ
- 硫化物
- 陰イオン
- イオン
- 電解質
- 硫化水素
- ダウノルビシン
- 化学物質の診断使用
- 経済
- ドキソルビシン
- パクリタキセル
- 免疫グロブリンG
- トポテカン
- 標本処理
- 磁気共鳴分光法
- Durvalumab
- ジスルフィド
- リポソームドキソルビシン
- オラパリブ
- セディラニブ
- コントラストメディア
- 税金
その他の研究ID番号
- NCI-2021-00615
- U10CA180868 (米国 NIH グラント/契約)
- NCI-2021-00615 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
- NRG-GY023 (その他の識別子:CTEP)
- NRG-GY023 (その他の識別子:NRG Oncology)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。